BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Adenocarcinoma, Clear Cell
/ drug therapy
Adult
Aged
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Biomarkers, Tumor
/ genetics
Cystadenocarcinoma, Serous
/ drug therapy
DNA Methylation
Endometrial Neoplasms
/ drug therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Mutation
Ovarian Neoplasms
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ therapeutic use
Prognosis
Promoter Regions, Genetic
Retrospective Studies
Survival Rate
BRCA genes
PARP inhibitors
ovarian cancer
promoter methylation
pyrosequencing
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Dec 2020
19 Dec 2020
Historique:
received:
17
11
2020
revised:
16
12
2020
accepted:
17
12
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
2
4
2021
Statut:
epublish
Résumé
Homologous Recombination Deficiency (HRD) is a frequent feature of high-grade epithelial ovarian carcinoma (EOC), associated with sensitivity to PARP-inhibitors (PARPi). The best characterized causes of HRD in EOCs are germline or somatic mutations in
Identifiants
pubmed: 33352687
pii: ijms21249708
doi: 10.3390/ijms21249708
pmc: PMC7767143
pii:
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Biomarkers, Tumor
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AstraZeneca
ID : -
Références
Sci Rep. 2014 Feb 07;4:4026
pubmed: 24504028
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Gynecol Oncol. 2018 Feb;148(2):281-285
pubmed: 29233532
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Cancer Genet Cytogenet. 2005 Jun;159(2):114-22
pubmed: 15899382
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Breast Cancer Res. 2017 May 31;19(1):64
pubmed: 28569220
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Cancer Genet. 2019 Sep;237:55-62
pubmed: 31447066
Ann Oncol. 2020 Dec;31(12):1606-1622
pubmed: 33004253
Ann Oncol. 2016 Aug;27(8):1449-55
pubmed: 27037296
Mol Cancer. 2009 Jul 14;8:48
pubmed: 19602291
J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203
pubmed: 32413141
Cancers (Basel). 2020 Apr 08;12(4):
pubmed: 32276467
Eur J Cancer. 2014 Aug;50(12):2090-8
pubmed: 24889916
Oncogene. 1998 Oct 8;17(14):1807-12
pubmed: 9778046
Cancer Genet. 2012 Jan-Feb;205(1-2):34-41
pubmed: 22429596
Nat Genet. 2010 May;42(5):410-4
pubmed: 20400964
Epigenetics. 2012 Nov;7(11):1225-9
pubmed: 23069641
Gynecol Oncol. 2006 Jun;101(3):403-10
pubmed: 16360812
Cancer Res. 2000 Oct 1;60(19):5329-33
pubmed: 11034065
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Nat Genet. 2011 Oct 02;43(11):1104-7
pubmed: 21964575
Crit Rev Oncol Hematol. 2019 Aug;140:67-72
pubmed: 31176273
Nat Genet. 2011 Aug 07;43(9):879-882
pubmed: 21822267
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Clin Cancer Res. 2017 Aug 1;23(15):4086-4094
pubmed: 28223274